CA3145338A1 - New heterocyclic compounds - Google Patents

New heterocyclic compounds Download PDF

Info

Publication number
CA3145338A1
CA3145338A1 CA3145338A CA3145338A CA3145338A1 CA 3145338 A1 CA3145338 A1 CA 3145338A1 CA 3145338 A CA3145338 A CA 3145338A CA 3145338 A CA3145338 A CA 3145338A CA 3145338 A1 CA3145338 A1 CA 3145338A1
Authority
CA
Canada
Prior art keywords
chloro
formula
compound
fluoro
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3145338A
Other languages
English (en)
French (fr)
Inventor
Carsten KROLL
Flore REGGIANI
Miroslav KOSAR
Maurice BIEDERMANN
Bernd Kuhn
Benoit Hornsperger
Uwe Grether
Fionn O`HARA
Hans Richter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67220669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3145338(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA3145338A1 publication Critical patent/CA3145338A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3145338A 2019-07-09 2020-07-07 New heterocyclic compounds Pending CA3145338A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19185088.2 2019-07-09
EP19185088 2019-07-09
PCT/EP2020/069074 WO2021005034A1 (en) 2019-07-09 2020-07-07 New heterocyclic compounds

Publications (1)

Publication Number Publication Date
CA3145338A1 true CA3145338A1 (en) 2021-01-14

Family

ID=67220669

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3145338A Pending CA3145338A1 (en) 2019-07-09 2020-07-07 New heterocyclic compounds

Country Status (19)

Country Link
US (1) US20220242876A1 (https=)
EP (1) EP3997096B1 (https=)
JP (1) JP7649283B2 (https=)
KR (1) KR20220034104A (https=)
CN (1) CN114096545A (https=)
AR (1) AR119376A1 (https=)
AU (1) AU2020311584A1 (https=)
BR (1) BR112021026899A2 (https=)
CA (1) CA3145338A1 (https=)
CL (1) CL2022000019A1 (https=)
CO (1) CO2022000186A2 (https=)
CR (1) CR20220004A (https=)
IL (1) IL288987A (https=)
MX (1) MX2022000243A (https=)
PE (1) PE20220515A1 (https=)
PH (1) PH12021553249A1 (https=)
TW (1) TW202116781A (https=)
WO (1) WO2021005034A1 (https=)
ZA (1) ZA202110352B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019134985A1 (en) 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
PE20211089A1 (es) 2018-08-13 2021-06-14 Hoffmann La Roche Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa
WO2020104494A1 (en) 2018-11-22 2020-05-28 F. Hoffmann-La Roche Ag New heterocyclic compounds
CN114269755A (zh) 2019-09-12 2022-04-01 豪夫迈·罗氏有限公司 作为magl抑制剂的4,4a,5,7,8,8a-六吡啶并[4,3-b][1,4]噁嗪-3-酮化合物
CA3190277A1 (en) 2020-09-03 2022-03-10 Joerg Benz Heterocyclic compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014001946A (es) * 2011-08-19 2014-03-27 Merck Sharp & Dohme Inhibidores del canal de potasio medularmente externo renal.
US9573961B2 (en) 2012-12-19 2017-02-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2017087863A1 (en) * 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
EP3571202B1 (en) * 2017-01-23 2021-06-30 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
JOP20190267A1 (ar) * 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl
JP7257387B2 (ja) * 2017-08-29 2023-04-13 ハー・ルンドベック・アクチエゼルスカベット スピロ環化合物並びにその作製及び使用方法
WO2019134985A1 (en) * 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
MX2022000083A (es) * 2019-07-03 2022-02-03 Hoffmann La Roche Inhibidores de monoacilglicerol lipasa (magl) heterociclicos.

Also Published As

Publication number Publication date
PH12021553249A1 (en) 2023-02-27
BR112021026899A2 (pt) 2022-05-10
EP3997096A1 (en) 2022-05-18
ZA202110352B (en) 2022-08-31
TW202116781A (zh) 2021-05-01
CR20220004A (es) 2022-01-31
WO2021005034A1 (en) 2021-01-14
EP3997096C0 (en) 2024-08-28
CL2022000019A1 (es) 2022-10-21
IL288987A (en) 2022-02-01
CO2022000186A2 (es) 2022-01-17
PE20220515A1 (es) 2022-04-07
AR119376A1 (es) 2021-12-15
JP7649283B2 (ja) 2025-03-19
EP3997096B1 (en) 2024-08-28
KR20220034104A (ko) 2022-03-17
MX2022000243A (es) 2022-02-03
JP2022539604A (ja) 2022-09-12
US20220242876A1 (en) 2022-08-04
AU2020311584A1 (en) 2022-01-20
CN114096545A (zh) 2022-02-25

Similar Documents

Publication Publication Date Title
EP3997096B1 (en) New heterocyclic compounds
AU2019238381B2 (en) Oxazine monoacylglycerol lipase (MAGL) inhibitors
JP7609854B2 (ja) Ｍａｇｌ阻害剤としての４，４ａ，５，７，８，８ａ－ヘキサピリド［４，３－ｂ］［１，４］オキサジン－３－オン化合物
US20210277020A1 (en) Heterocyclic compounds as monoacylglycerol lipase inhibitors
CN114401968A (zh) 新颖杂环单酰基甘油脂肪酶(magl)抑制剂
CA3215260A1 (en) Heterocyclic compounds
EP3994137A1 (en) Heterocyclic monoacylglycerol lipase (magl) inhibitors
WO2021058444A1 (en) Heterocyclic compounds
CA3151218A1 (en) 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
WO2023062049A1 (en) Heterocyclic compounds
WO2025068347A1 (en) New heterocyclic compounds
HK40065118A (en) New heterocyclic monoacylglycerol lipase (magl) inhibitors
HK40068386A (en) New heterocyclic compounds

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251204

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260129

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260204